Revelation Biosciences finishes dosing for five single dose cohorts

Clinical stage life sciences company Revelation Biosciences Inc. recently announced that it has been conceded approval to make an addition of a multiple dose cohort to its Phase-1 clinical study of REVTx 99 in healthy volunteers by the Bellberry Human Research Ethics Committee (HREC) in Australia.



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK